Patent Expiry Strategy Through Authorized Generics

Global pharmaceutical company Eli Lilly (LLY) has partnered with Prasco Laboratories to launch an authorized generic of its osteoporosis treatment, Forteo (active ingredient: teriparatide), in response to the drug's patent expiry. Forteo is a recombinant human parathyroid hormone (rhPTH 1-34) that stimulates the parathyroid hormone 1 receptor (PTH1R) to promote bone formation. Since receiving FDA approval on November 26, 2002, it has been a blockbuster drug, generating peak annual sales of USD 1.7 billion prior to patent expiration. The companies' recent regulatory data submission is seen as a strategic move to ensure a stable supply of high-quality generics produced in the same manufacturing process as the original drug, even after patent expiry.

A Dual Strategy of Market Defense and Asset Optimization

In the biopharmaceutical industry, originator drugs often experience a sharp decline in sales after patent expiry due to competition from low-cost generics. Eli Lilly is leveraging Prasco to supply authorized generics using its existing manufacturing facilities, allowing it to capture a portion of the generic market share and maintain factory utilization rates. Prasco, in turn, benefits from distributing the proven Eli Lilly product under its own brand, securing strong market credibility without significant capital investment. This is considered a win-win strategy that allows them to gain an advantage in price competition with generic competitors such as Teva and Apotex, while maximizing distribution partnerships.

Intense Competition in the Osteoporosis Treatment Market

The global osteoporosis treatment market, valued at approximately USD 14 billion to 17.6 billion, is a large and growing market driven by the aging population. Key players in the market include Radius Health's Tymlos (active ingredient: abaloparatide), a parathyroid hormone receptor agonist, and Amgen's bone resorption inhibitors, Prolia (active ingredient: denosumab) and Evenity (active ingredient: romosozumab). In this competitive landscape, Prasco's authorized generic, which offers the same convenience and safety as the original drug, is positioned as an attractive alternative for both patients and payers due to its cost-effectiveness.

Ensuring Regulatory Compliance and Supply Chain Security

The FDA's recent directives regarding packaging specifications and labeling changes for teriparatide formulations demonstrate the strict quality control standards applied to generic drugs. Given the specialized nature of the drug, which uses a pen-type precision injection device, Prasco's distribution model, which shares Eli Lilly's validated manufacturing facilities, significantly contributes to minimizing the risk of medication errors in patients. This ongoing collaboration under the close monitoring of regulatory authorities is considered a prime example of addressing two key challenges simultaneously: managing the lifecycle of complex biologics and ensuring continuity of patient care.